CLOs on the Move

Avita Medical

www.avitamedical.com

 
Avita Medical is a publicly listed regenerative medicine company trading on the Australian Stock Exchange (ASX:AVH) and OTC Markets (OTCQX:AVMXY). The company`s lead product, ReCell® is used in a wide variety of burns, chronic wounds, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA- registered in Australia, and SFDA-cleared in China. ReCell is not available for sale in the United States; in the US ReCell is an investigational device limited by federal law to investigational use.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Brett Silton
Head of Corporate Compliance Profile
Donna Shiroma
General Counsel Profile

Similar Companies

Neometrics Inc

Neometrics Inc is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Eastern States Eyewear

Eastern States Eyewear is a Elmont, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Futuremed America Inc

Futuremed America Inc is a Granada Hills, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

iHealth Lab

iHealth is dedicated to helping people lead healthier lives.   Our goal is to make it as easy as possible for individuals of all ages to take a more active role in managing their health.   We do this by designing and manufacturing innovative, consumer-friendly, mobile personal healthcare products that connect to the cloud. Our products are easy-to-use, making it simple for consumers to accurately measure, track and share a full range of health vitals. By automatically connecting the data through the cloud, consumers are able to see a more comprehensive view of their vitals and easily share information with healthcare professionals or loved ones.   Our award-winning line of products include blood pressure monitors, blood glucose monitors, body analysis scales, pulse oximeters and activity and sleep trackers. All of our products sync directly with a free mobile app that makes monitoring, viewing, storing and sharing of health vitals simple and comprehensive.

OXiGENE

OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.